← Back to screener

Revolution Medicines, Inc. RVMD

Rank #2414 · Nasdaq · $40.7B market cap
Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.
Score
19.8
P/E
-93.2
P/B
59.36
ROE
-63.7%
Op. Margin
-4207.1%
Debt Ratio
43%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -93.2x, P/B 59.36x. Ranks in the top 81% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -63.7%. Ranks in the top 94% of the universe.

Safety ★★★★☆
Good

Debt ratio 43%. Ranks in the top 21% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 67.3% year over year. Ranks in the top 98% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2020$0.0B$-0.0B$-0.0B$-0.1B-200.0-100
2021$0.1B$-0.1B$-0.0B$-0.1B-108.2-86
2022$0.0B$-0.1B$-0.1B$-0.2B-257.5-89
2023$0.0B$-0.2B$-0.2B$0.5B-639.727
2024$0.0B$-0.3B$-0.2B$0.6B-730.039
2025$0.0B$-0.5B$-0.4B$0.7B-4207.143

← See the full screener